Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Cereblon ligand-induced BET degradation-based bifunctional molecule and preparation and application thereof

A small molecule ligand and reaction technology, applied in organic chemistry, drug combination, anti-tumor drugs, etc., can solve problems such as thrombocytopenia, toxic side effects, and unsatisfactory anti-tumor effects of drugs

Inactive Publication Date: 2017-08-18
CHINA PHARM UNIV
View PDF3 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Phase I clinical results of OTX-015 show that when the dose is higher than 80mg per day, patients will experience severe side effects: thrombocytopenia, and when the dose is lower, the anti-tumor effect of the drug is not satisfactory

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cereblon ligand-induced BET degradation-based bifunctional molecule and preparation and application thereof
  • Cereblon ligand-induced BET degradation-based bifunctional molecule and preparation and application thereof
  • Cereblon ligand-induced BET degradation-based bifunctional molecule and preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1: Preparation of 2-(2-(4-((6-(3,5-dimethylisoxazol-4-yl)-1-methyl-2-oxo-4-phenyl-1 , 4-dihydroquinazolin-3(2H)-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)-N-(2-(2,6 -Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4-yl)acetamide (I-1), its structural formula is as follows:

[0068]

[0069] Step 1) 2-Hydroxyethyl-4-methylbenzenesulfonate (1a)

[0070]

[0071] Dissolve ethylene glycol (3.91g, 62.95mmol) in 5mL of pyridine, add p-toluenesulfonyl chloride (6g, 31.47mmol) in batches, stir at room temperature for 4 hours, add 6mol / L hydrochloric acid (40mL), wash with ethyl acetate Extract, wash with saturated brine, collect the organic layer, dry over anhydrous sodium sulfate, evaporate the organic solvent under reduced pressure, and purify the residue by silica gel column chromatography using petroleum ether / ethyl acetate (V / V=20 / 1-10 / 1) was eluted to obtain a colorless liquid weighing 2 g with a yield of 29.39%.

[0072] 1 H NMR (300MHz, CDCl 3 )δ7.81(d, J=8....

Embodiment 2

[0094] Example 2: Preparation of 2-(2-(2-(4-((6-(3,5-dimethylisoxazol-4-yl)-1-methyl-2-oxo-4-benzene Base-1,4-dihydroquinazolin-3(2H)-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)-N- (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4-yl)acetamide (I-2), its structural formula is as follows:

[0095]

[0096] Synthetic steps are with embodiment 1

[0097] MS (ESI, m / z): 838.05 [M+Na] +

[0098] 1 H NMR (300MHz, CDCl 3 )δ10.44(d, J=5.9Hz, 1H), 9.20(s, 1H), 8.85(d, J=8.2Hz, 1H), 7.77-7.66(m, 2H), 7.57(d, J=7.3 Hz, 1H), 7.39-7.27(m, 5H), 7.07(d, J=8.4Hz, 1H), 6.90(d, J=8.7Hz, 2H), 5.79(d, J=11.5Hz, 1H), 5.10(s, 1H), 4.98(s, 1H), 4.50(s, 2H), 4.19-3.84(m, 6H), 3.75(s, 4H), 3.41(s, 3H), 2.86(d, J= 13.4Hz, 4H), 2.20 (d, J = 41.5Hz, 9H).

Embodiment 3

[0099] Example 3: Preparation of 2-(2-(2-(2-(4-((6-(3,5-dimethylisoxazol-4-yl)-1-methyl-2-oxo- 4-phenyl-dihydroquinazolin-3(2H)-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy) -N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindoline-4-yl)acetamide (I-3), its structural formula is as follows:

[0100]

[0101] Synthetic steps are with embodiment 1

[0102] MS (ESI, m / z): 782.30 [M+Na] +

[0103] 1 H NMR (300MHz, CDCl 3 )δ10.47(s, 1H), 9.08(s, 1H), 8.86(d, J=8.3Hz, 1H), 8.08-7.53(m, 3H), 7.31(d, J=16.6Hz, 5H), 7.09(d, J=7.7Hz, 1H), 6.93(d, J=8.4Hz, 2H), 5.84(s, 1H), 4.98(s, 1H), 4.51(s, 2H), 4.20(s, 2H ), 3.84-3.34 (m, 14H), 2.82 (s, 4H), 2.29 (s, 3H), 2.15 (s, 4H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel preparation method of a bifunctional molecule and a pharmaceutically acceptable salt, hydrate or prodrug thereof and application of these compounds and a medicinal composition thereof in treatment of diseases such as tumors, inflammation and immunity. The bifunctional molecule is a protein degradation-targeted complex (PROTACs), and is capable of selectively inducing BET protein degradation. A BET protein small-molecule inhibitor is connected with a cereblon protein ligand in an E3 ubiquitin ligase complex to obtain the bifunctional molecule.

Description

technical field [0001] The present invention relates to the preparation method of new bifunctional small molecules and their pharmaceutically acceptable salts, hydrates or prodrugs and the application of these compounds and their pharmaceutical compositions in treating diseases such as tumors, inflammation and immunity. The bifunctional small molecules involved in the present invention are protein degradation targeting complexes (PROTACs), which can selectively induce BET protein degradation. The invention obtains the bifunctional small molecule by connecting the BET protein small molecule inhibitor with the cereblon protein ligand in the E3 ubiquitin ligase complex by using a connecting arm. Background technique [0002] Cereblon is a protein encoded by the human CRBN gene, and the CRBN homologs are highly conserved, suggesting its importance in physiology. Cereblon forms an E3 ubiquitin ligase complex with damage DNA binding protein 1 (DDB1), Cullin-4A (CUL4A) and Cullin-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D413/14A61K31/517A61P35/00A61P35/02
CPCC07D413/14
Inventor 张惠斌周金培赵雷磊武振威杨一飞张剑李向阳
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com